Spots Global Cancer Trial Database for third line therapy
Every month we try and update this database with for third line therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung | NCT04496674 | Lung Cancer Squ... | CC-1 and Toczil... | 18 Years - | German Cancer Research Center | |
Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer | NCT01387880 | Metastatic Colo... | Everolimus Everolimus | 18 Years - | Herlev Hospital | |
Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer | NCT01387880 | Metastatic Colo... | Everolimus Everolimus | 18 Years - | Herlev Hospital | |
Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer | NCT01387880 | Metastatic Colo... | Everolimus Everolimus | 18 Years - | Herlev Hospital |